Health Catalyst stock downgraded by Cantor Fitzgerald amid revenue concerns

Health Catalyst Inc. (HCAT) has faced significant analyst downgrades, with Cantor Fitzgerald cutting its rating to Neutral and price target to $4.00 from $9.00, citing a deteriorating revenue outlook and multi-year headwinds following its Q2 2025 earnings call. BTIG also downgraded HCAT to Neutral due to concerns over potential legislative impacts on healthcare coverage. While management has maintained 2025 EBITDA guidance despite reduced revenue forecasts, analysts express concern over the challenging macroeconomic environment for healthcare data analytics, further compounded by the upcoming departure of CEO Dan Burton in June 2026.

Analysis

Health Catalyst (HCAT) is facing significant headwinds, evidenced by multiple recent analyst downgrades and a stock price trading near its 52-week low. Cantor Fitzgerald has notably cut its rating to Neutral from Overweight and slashed its price target to $4.00 from $9.00, citing a deteriorating revenue outlook with multi-year challenges following the company's Q2 2025 earnings call. This sentiment is echoed by BTIG, which also downgraded the stock to Neutral due to concerns over legislative changes potentially impacting healthcare coverage. While the company has shown 4.88% revenue growth over the last twelve months, a forward-looking negative trend is indicated by nine analysts revising earnings expectations downward. A key point of tension is management's ability to maintain 2025 EBITDA guidance despite lowering revenue forecasts—a sign of operational strength, yet analysts remain concerned about the challenging macroeconomic backdrop. Compounding this uncertainty is the announced departure of CEO Dan Burton in June 2026, introducing long-term leadership transition risk. Stifel's Hold rating with a $5.50 price target offers a more moderate view but still flags risks associated with government funding and the critical importance of closing late-stage deals to meet targets.

Key Decisions for Investors

• Given the multiple analyst downgrades, deteriorating revenue outlook, and upcoming CEO transition, investors should view the stock with significant caution as it faces considerable fundamental and leadership uncertainty.
• Prospective and current investors must closely monitor the company's ability to close its late-stage deal pipeline and any legislative developments impacting healthcare spending, as these are the primary risks highlighted by analysts.
• Despite the negative sentiment, management's success in maintaining EBITDA guidance could signal operational resilience, warranting a hold for high-risk tolerant investors who are waiting for clearer revenue stabilization and a defined CEO succession plan.